Roche Expands Global Access to Viral Assays to Aid Eradication Efforts
Roche has expanded the Global Access Program, originally established to increase availability of HIV diagnostics in underserved countries, to include diagnostic tests for tuberculosis, hepatitis, and human papillomavirus (HPV). Increased access to reliable diagnostics will allow early, possibly life-saving, detection and decrease the spread of these diseases.
Roche launched the program in 2014 and began offering the added tests in July. The molecular diagnostics available include tests for determination of HIV-1 viral load, early diagnosis of HIV-1 and -2 in young infants, Mycobacterium tuberculosis (MTB) and rifampin/isoniazid-resistant MTB, hepatitis B and C, and HPV. Depending on the test, assays run on Rocheâs cobas 4800/6800/8800 platforms. Samples can be collected in far-flung sites on the cobas Plasma Separation Card and transported to the testing centers for processing. Roche offers a special pricing scheme for the diagnostic tests to qualifying organizations in 82 eligible countries. The program also offers reduced pricing for the outright purchase of the cobas 4800/6800/8800 systems but does not include service and maintenance or third-party laboratory equipment.
âWe monitor the success of the Global Access Program by the number of diagnostic tests provided to those in greatest need,â Mario Torres, head of Roche Molecular Diagnostics, told MD+DI. âSince the inception of the program, the number o...
Source: MDDI - Category: Medical Devices Authors: Jenevieve Blair Polin Tags: IVD Source Type: news
More News: African Health | Cancer | Cancer & Oncology | Centers for Disease Control and Prevention (CDC) | Cervical Cancer | Department of Health | Emergency Medicine | Genital Warts | Hepatitis | Hepatitis B | HIV AIDS | HPV Testing | Human Papillomavirus (HPV) | Laboratory Medicine | Medical Devices | Pediatrics | Tuberculosis | United Nations | USA Health | Women